Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Update

by · The Cerbat Gem

Cel-Sci Corporation (NYSEAMERICAN:CVM – Get Free Report) was the recipient of a large drop in short interest during the month of May. As of May 15th, there was short interest totaling 255,031 shares, a drop of 64.0% from the April 30th total of 708,414 shares. Based on an average daily trading volume, of 1,289,720 shares, the short-interest ratio is currently 0.2 days. Approximately 3.3% of the shares of the company are sold short.

Hedge Funds Weigh In On Cel-Sci

Hedge funds and other institutional investors have recently bought and sold shares of the company. US Bancorp DE purchased a new position in Cel-Sci in the 3rd quarter valued at $80,000. HighTower Advisors LLC purchased a new stake in shares of Cel-Sci during the 4th quarter worth $53,000. HRT Financial LP purchased a new stake in shares of Cel-Sci during the 4th quarter worth $60,000. XTX Topco Ltd purchased a new stake in shares of Cel-Sci during the 4th quarter worth $66,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Cel-Sci during the 4th quarter worth $81,000. 12.08% of the stock is currently owned by hedge funds and other institutional investors.

Cel-Sci Stock Performance

NYSEAMERICAN:CVM traded down $0.06 during midday trading on Monday, reaching $1.48. The stock had a trading volume of 251,861 shares, compared to its average volume of 229,545. The firm has a fifty day simple moving average of $2.85 and a two-hundred day simple moving average of $4.49. Cel-Sci has a 12-month low of $0.89 and a 12-month high of $13.48. The company has a quick ratio of 0.54, a current ratio of 0.60 and a debt-to-equity ratio of 0.64. The stock has a market cap of $12.57 million, a P/E ratio of -0.15 and a beta of 0.54.

Cel-Sci (NYSEAMERICAN:CVM – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.67) earnings per share for the quarter.

About Cel-Sci

(Get Free Report)

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.

Read More